$-0.43 EPS Expected for Advaxis, Inc. (ADXS)

December 8, 2017 - By Winifred Garcia

 $ 0.43 EPS Expected for Advaxis, Inc. (ADXS)
Investors sentiment increased to 1.63 in Q2 2017. Its up 0.47, from 1.16 in 2017Q1. It increased, as 8 investors sold Advaxis, Inc. shares while 19 reduced holdings. 15 funds opened positions while 29 raised stakes. 19.46 million shares or 9.11% less from 21.41 million shares in 2017Q1 were reported.
Ontario – Canada-based Manufacturers Life Ins Com The has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Barclays Public Ltd Llc reported 14,844 shares stake. Focused Wealth Mgmt holds 275 shares or 0% of its portfolio. Nationwide Fund Advsrs accumulated 20,462 shares or 0% of the stock. Sg Americas Limited Com has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). California-based Stonebridge Capital Inc has invested 0.06% in Advaxis, Inc. (NASDAQ:ADXS). Orca Management Limited Company holds 0.06% or 10,000 shares in its portfolio. Vident Investment Advisory Ltd Liability Co holds 187,041 shares. 173,753 were reported by Bancshares Of New York Mellon. Schwab Charles Investment Management Inc has 129,321 shares. Wells Fargo & Mn holds 44,813 shares. State Board Of Administration Of Florida Retirement has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). California State Teachers Retirement System holds 64,641 shares. Vanguard Grp reported 1.78M shares or 0% of all its holdings. Blackrock accumulated 2.26M shares.

Analysts expect Advaxis, Inc. (NASDAQ:ADXS) to report $-0.43 EPS on January, 8.After having $-0.80 EPS previously, Advaxis, Inc.’s analysts see -46.25 % EPS growth. The stock decreased 0.70% or $0.02 during the last trading session, reaching $2.85. About 436,241 shares traded. Advaxis, Inc. (NASDAQ:ADXS) has risen 11.01% since December 8, 2016 and is uptrending. It has underperformed by 5.69% the S&P500.

Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage

Among 4 analysts covering Advaxis (NASDAQ:ADXS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Advaxis had 7 analyst reports since September 11, 2015 according to SRatingsIntel. Barclays Capital initiated it with “Overweight” rating and $40 target in Tuesday, September 22 report. The stock has “Buy” rating by Cantor Fitzgerald on Monday, June 12. The firm has “Buy” rating by Guggenheim given on Friday, September 11. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, May 31. The rating was maintained by Cantor Fitzgerald on Thursday, July 6 with “Buy”. The stock of Advaxis, Inc. (NASDAQ:ADXS) has “Buy” rating given on Wednesday, June 14 by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, November 8.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The company has market cap of $117.04 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. It currently has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

Another recent and important Advaxis, Inc. (NASDAQ:ADXS) news was published by Businesswire.com which published an article titled: “Advaxis to Present at the Jefferies 2017 London Healthcare Conference” on November 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.